ArticleBMC gastroenterology2025
A retrospective study on the efficacy of ex vivo liver resection combined with autologous liver transplantation in treating advanced alveolar echinococcosis at high altitude.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the Feasibility and efficacy of total ex vivo liver resection combined with autologous liver transplantation for the treatment of advanced alveolar echinococcosis in high-altitude regions.
methodsA retrospective (consecutive) analysis was conducted on 19 patients who underwent ex vivo liver resection with autologous liver transplantation at Qinghai Provincial People’s Hospital between May 2013 and December 2024. Patient data, including age, gender, ethnicity, intraoperative blood loss, operative time, and follow-up duration, were collected and subjected to descriptive statistics and comparative analysis.
resultsAll 19 patients with advanced hepatic alveolar echinococcosis (HAE) successfully underwent ex vivo liver resection with autotransplantation (ELRA) with no intraoperative mortality. Postoperative complications occurred in 84.2% (16/19) of cases. Perioperative mortality was 15.8% (3/19), including deaths due to massive intra-abdominal hemorrhage (1 case), intracranial hemorrhage (1 case), and septic shock (1 case). The median operative time was 840 min (range, 500–1277), with a median intraoperative blood loss of 2000 mL (range, 600–12000 mL). Inferior vena cava reconstruction primarily utilized synthetic graft interposition (63.2%, 12/19), while portal vein reconstruction mostly employed suture repair (89.5%, 17/19). Among 16 surviving patients, the median follow-up duration was 595 days, with no recurrence of HAE observed. Three additional deaths occurred during follow-up. ELRA demonstrated technical feasibility in high-altitude regions but requires vigilant monitoring for unique complications such as postoperative intracranial hemorrhage.
conclusionDespite the elevated surgical risks imposed by the unique high-altitude environment, total ex vivo liver resection combined with autologous liver transplantation demonstrates feasibility and potential clinical value as a treatment option for advanced hepatic alveolar echinococcosis (HAE) in plateau regions. This technique significantly improves patients’ quality of life and long-term prognosis, demonstrating strong feasibility and clinical efficacy. It thus represents a valuable new treatment option for patients with end-stage HAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.